Circulating Tumor DNA Longitudinal Analysis During Total Neoadjuvant Therapy and Non-operative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Biomarker study evaluates ctDNA's association with treatment response and outcomes in locally advanced rectal cancer, suggesting its predictive potential.
Key Points
Baseline circulating tumor DNA detection was 98.4%, dropping to 5% post-treatment based on multiple evaluations.
ctDNA clearance was 100% in patients achieving clinical complete response, indicating its predictive value in treatment response.
This prospective trial enrolled 64 patients with locally advanced rectal cancer, testing ctDNA at various treatment stages.
The findings highlight ctDNA's potential as a prognostic biomarker in rectal cancer treatment management, despite modest sensitivity.